Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HMGCR | P04035 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018553 | 0.87 | HTT (0.47) | HTTGAAHSP90AA1KDM4EPOLB | |
| SCHEMBL382174 | 0.86 | GAA (0.50) | HTTGAAKDM4EPOLBRECQL | |
| SCHEMBL1021339 | 0.85 | KDM4E (0.49) | HTTHSP90AA1KDM4EPOLBRECQL | |
| SCHEMBL1018849 | 0.84 | HSP90AA1 (0.56) | GAAHSP90AA1KDM4EPOLBCA12 | |
| SCHEMBL1018764 | 0.83 | HSP90AA1 (0.44) | GAAHSP90AA1CA12CA1CA2 | |
| SCHEMBL18318870 | 0.82 | GAA (0.58) | HTTGAAKDM4EPOLBLMNA | |
| SCHEMBL23159299 | 0.80 | HSP90AA1 (0.46) | GAAHSP90AA1KDM4EPOLBCA12 | |
| SCHEMBL15614388 | 0.80 | KDM4E (0.45) | HTTGAAKDM4EPOLBRECQL | |
| SCHEMBL1020114 | 0.80 | HSP90AA1 (0.42) | GAAHSP90AA1KDM4ETSHRMAPT | |
| SCHEMBL20379942 | 0.80 | HTT (0.48) | HTTGAAHSP90AA1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2271618-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210820-A1 | Pharmaceutical Compounds | SLC10A1, MAPT, SLC5A1 | HTT 313/4885GAA 1031/4885HSP90AA1 2662/4885 |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | NR3C2, NR5A2, NR0B1 | HTT 1259/4885GAA 4684/4885HSP90AA1 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.